CD44-Modulating Polypeptides for Cancer Treatment and Ascites Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies are inadequate for effectively treating tumors and inhibiting metastasis in cancer patients, particularly in modulating CD44 activity to prevent drug efflux and addressing associated conditions like ascites.
Innovation Solution
Development of CD44-modulating polypeptides, such as monoclonal antibodies and peptides, that bind to specific regions of CD44 to inhibit its activity, potentially combined with secondary therapies like chemotherapy or radiation, to treat various cancers and ascites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatment strategies are used, then treatment is simpler, but tumor treatment efficacy is insufficient and metastasis cannot be effectively inhibited
Solution Approach 1:
The patent introduces anti-CD44 antibodies as intermediary agents that specifically bind to CD44 proteins on cancer cell surfaces. These antibodies mediate the treatment effect by blocking CD44 function and inducing immune responses, thereby enhancing tumor treatment efficacy without requiring complex multi-component systems
Solution Approach 2:
The patent utilizes parameter changes in antibody structure and binding affinity to optimize treatment efficacy. By engineering antibodies with specific binding characteristics to CD44 epitopes, the treatment achieves enhanced effectiveness while maintaining a relatively simple administration protocol
2Reliability
If CD44 activity is not modulated, then drug efflux occurs reducing treatment efficacy, but adding CD44 modulation increases treatment complexity
Solution Approach 1:
Anti-CD44 antibodies serve as intermediary molecules that bind to CD44 receptors, preventing drug-efflux interacting proteins from accessing their targets. This intermediary action blocks the efflux pathway and improves drug retention within cancer cells
Solution Approach 2:
The patent extracts and targets the specific CD44 molecular pathway responsible for drug efflux. By isolating and blocking this specific mechanism with targeted antibodies, the treatment prevents drug efflux without requiring complex multi-target approaches
3Reliability
If ascites is not addressed, then cancer progression continues, but treating ascites separately increases treatment complexity
Solution Approach 1:
The anti-CD44 antibody treatment exhibits multi-functionality by simultaneously addressing primary tumor growth and secondary complications like ascites. This single therapeutic agent performs multiple functions: inhibiting tumor proliferation, preventing metastasis, and managing ascites formation through CD44 pathway blockade
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CD44-modulating polypeptides effectively inhibit CD44 activity, enhancing the efficacy of treatments for cancers like ovarian, breast, and lung cancer, and reducing ascites volumes, while being safe and well-tolerated in clinical trials.
Implementation Method 1
the monoclonal antibodies (or fragments thereof) may be specific for the cryptic region of CD44, or a portion thereof
Data Source
AI summary
Methods and CD44-modulating peptide compositions for treating or ameliorating ascites, for treating or ameliorating a tumor or cancer, wherein the compositions feature binding moieties such as monoclonal antibodies or fragments thereof specific for CD44 that inhibit CD44 activity, or CD44-modulating peptides that bind to and modulate activity of CD44, optionally featuring a pharmaceutically acceptable carrier. The binding moieties herein may be used with a secondary therapy. In some embodiments, the monoclonal antibody or fragment thereof binds to at least a portion of the cryptic region of CD44.